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IntroductIon
Vascular endothelial growth factor (VEGF) is the main growth 
factor responsible for angiogenesis which also mediates retinal 
neovascularization in retinopathy of prematurity (ROP).1 
Insulin‑like growth factor‑1 (IGF‑1) is also critical for 
normal vascular formation, and its low serum level is strongly 
associated with the development of ROP. 2
Bevacizumab (Avastin®; Genentech, Inc., South San Francisco, 
CA, USA) is a recombinant humanized monoclonal antibody 
that is directed against VEGF‑A. Intravitreal injection of the 
bevacizumab (IVB) has been used as a treatment modality 
for Type 1 ROP. 3 A major concern regarding anti‑VEGF 
therapy in ROP is the risk of systemic absorption. There are 
few studies that evaluated serum concentration of VEGF after 
IVB in infants with ROP, and all of them have consensus in a 
significant reduction of serum VEGF level following IVB.4‑7
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Purpose: To determine the changes in serum levels of free vascular endothelial growth factor (VEGF), insulin‑like growth factor‑1 (IGF‑1), 
and growth parameters in infants with retinopathy of prematurity (ROP) who received intravitreal injection of the bevacizumab (IVB).
Methods: A prospective interventional case series study, including 10 infants with Type 1 ROP was conducted. Using the enzyme‑linked 
immunosorbent assay, serum levels of VEGF and IGF‑1 were measured before, 1 month and 2 months after treatment with IVB in both eyes. 
Growth parameters, including weight, length, and head circumference and their Fenton’s z‑score, were also measured.
Results: Serum VEGF levels were suppressed 1 month after IVB (P = 0.007) and then increased between 1 and 2 months (P = 0.064). Z‑scores 
of all growth parameters except weight z‑score decreased in the 1st and 2nd months.
Conclusion: Serum VEGF levels showed a transient reduction after IVB which lasted at least 2 months. Growth velocity of premature infants 
may be affected by anti‑VEGF therapy and should be followed with particular attention.
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Concerns have been raised about systemic absorption 
of bevacizumab and its effect on developing tissues, 
including the brain. A decrease in serum levels of VEGF 
and dependent factors, especially IGF‑1, has potential side 
effects such as impaired neurogenesis and neuroprotection.8,9 
Head circumference growth has special relevance to 
neurodevelopment in preterm infants, which is used as 
an indicator of brain size.10 On the other hand, the role of 
suboptimal postnatal growth of head circumference11 and 
weight12 has been established in the development of ROP. 
Therefore, anti‑VEGF drugs can change infantile growth 
parameters such as weight, length, and head circumference by 
alleviating ROP stage or slowing growth speed. To the best of 
our knowledge, there is only one study which evaluated the 
body weight gain in infants with ROP who had undergone IVB 
and laser therapy, and found no change after both treatments.4 
Recruitment of other growth indices such as body length and 
head circumference is less addressed.
The aims of this study were to: (1) evaluate serum concentrations 
of VEGF and IGF‑1 in infants with ROP who received IVB up 
to 2 months and (2) evaluate the changes in three main growth 
parameters after IVB using Fenton’s z‑scores (it is a measure 
of deviation from the mean adjusted for gestational age [GA]).
Methods
This study was a prospective interventional case series 
on infants with Type 1 ROP referred to a university 
hospital (Rassoul Akram Hospital, Tehran, Iran) from 
July 2016 to December 2017. Informed consents from the 
parents of all patients and Ethics Committee approval of Iran 
University of Medical Sciences (IUMS) (IUMS‑9311257003) 
were obtained. This study adhered to the tenets of the 
Declaration of Helsinki. ROP screening was performed with 
dilated fundus examination. The stage of the ROP determined 
according to the International Classification of Prematurity 
System.13
Included were infants with ROP Type 1, Stage 3+ ROP 
in zone I or zone II posterior in both eyes.  Based on the 
BEAT‑ROP study,3 infants underwent intravitreal injection 
of bevacizumab (0.625 mg/0.025 ml) per eye per dose by 
topical anesthesia with a 30G needle, 1.5 mm posterior to 
the corneal limbus under sterile conditions in the operating 
room. After the injection procedure, topical antibiotics and 
steroid eye drops were prescribed. Both eyes were treated in 
all patients. Exclusion criteria were history of laser therapy 
or laser therapy after IVB. The infants who underwent pre‑ or 
post‑IVB whole blood transfusion were also excluded due to 
the possible changes of the anti‑VEGF systemic level as well 
as poor health status of patients.
The following data were gathered: stage of ROP at enrollment, 
gender, GA, postmenstrual age (PMA) at the time of 
treatment, and birth weight. Body weight, body length, and 
head circumference were also measured before, 1 month, and 
2 months after treatment.
The measurement of serum level of vascular endothelial 
growth factor and insulin‑like growth factor‑1
Blood samples were collected just before IVB injection as well 
as at 1 month and at 2 months after treatment. The blood samples 
were collected in sterile tubes with ethylenediaminetetraacetic 
acid and centrifuged at 5000 revolutions per minute for 10 min 
until a clear separation between plasma and cellular parts 
became visible. After centrifugation, blood plasma was kept 
frozen at − 80°C until analysis was performed. Enzyme‑linked 
immunosorbent assay (ELISA) kits (Quantikine ELISA 
for human VEGF and human IGF‑1; RandD Systems, 
Minneapolis, MN, USA) were used to measure the serum 
levels of free VEGF and IGF‑1. Working standards were 
provided based on the manufacturer’s recommendations. The 
results were applied to a microplate reader at wavelengths of 
450 nm and 570 nm for all values. All assays were performed 
in duplicate to acquire an average.
Fenton and Kim14 growth z‑scores were calculated for growth 
parameters, including weight, head circumference, and body 
length. We chose to use z‑scores rather than crude amount of 
weight, head circumference, and length measurements because 
this provides standardization to a recognized scale, widely used 
and validated.14 The negative change in z‑score represents the 
less than the predicted growth rate whereas a positive change 
indicates a growth rate greater than the expected rate.14
Statistical analysis
Data were analyzed using SPSS software (version 22.0, 
IBM Corporation, Armonk, NY, USA). Normal distribution 
of data was evaluated by Shapiro–Wilk test because of the 
≤50 number of sample size. Repeated measures ANOVA with 
a Greenhouse–Geisser correction was used to evaluate the 
changes of variables at follow‑up times. Post hoc tests using the 
Bonferroni correction was used to compare follow‑up times. 
P < 0.05 was considered statistically significant except post hoc 
comparison that was set at a significant level of <0.017 based 
on a Bonferroni correction.
results
We initially enrolled 14 patients in this study; however, four 
patients were excluded due to severe cardiopulmonary disease 
that could confound the relationship between serum level 
of VEGF and infantile growth. Finally, 10 infants (4 boys 
and 6 girls) with ROP Type 1, Stage 3+ ROP in zone I or 
zone II posterior in both eyes were included. The infants 
had a mean GA of 27.5 ± 2.8 weeks and a mean PMA of 
34.0 ± 1.9 weeks (ranging from 31 to 37 weeks). The mean 
birth weight of infants was 1279.0 ± 364.7 (ranging from 
820 to 3050 grams). Table 1 shows baseline growth parameters.
All data had normal distribution based on Shapiro–Wilk 
test (0.075 ≤ P ≤ 0.899).
Serum levels of free vascular endothelial growth factor
Serum‑free VEGF levels had significant changes after 
IVB (P = 0.002). They decreased 774.00 ± 581.36 pg/ml at 
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month 1, which was significant (P = 0.007) and remained lower 
than pretreatment levels after 2 months (P = 0.001) [Figure 1].
Serum levels of insulin‑like growth factor‑1
Serum IGF‑1 levels did not have significant changes during 
2‑month follow‑up (P = 0.062), including reduction of 
1.28 ± 9.80 ng/ml at month 1 (P = 1.00) and then 6.51 ± 7.38 ng/ml 
increase at month 2 (P = 0.063) [Figure 2 and Table 1].
Growth pattern
All growth parameters showed a continuous increase over 
time. However, z‑scores of all growth parameters except 
the z‑score of weight decreased in the 1st and 2nd months 
[Figure 3 and Table 1]. Up to 2 months following treatment, 
a weak positive correlation was detected between the IGF‑1 
serum levels and the infant’s weight (rs = 0.4, P = 0.033), 
length (rs = 0.4, P = 0.029), and head circumference (rs = 0.4, 
P = 0.036) on the day that the serum was collected. However, 
the VEGF level did not have any correlation with growth 
parameters and IGF‑1 levels (0.086 < P < 0.983). Furthermore, 
the Spearman correlation test was done between the declines 
of serum bevacizumab versus changes of the z‑scores of 
the anthropometric indices. No significant correlation was 
found (0.21 ≤ P ≤ 0.93).
dIscussIon
Bevacizumab (Avastin) is an anti‑VEGF agent which leaks 
from the vitreous cavity into the systemic circulation and 
suppresses the VEGF levels in infants with ROP. 4‑7 The highest 
blood level of bevacizumab is attained around one to 2 weeks 
after the intravitreal injection.15 Significant reduction of serum 
VEGF level 1 month after IVB (P = 0.007) and its rise up to 
month 2 in our study is consistent with the short‑term systemic 
effect of bevacizumab in infants.4,6 Furthermore, IVB was 
injected in both eyes in the current study, which may affect the 
systemic VEGF more than unilateral injections.
Dysregulation of other cytokines, such as IGF‑1, may happen 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1: Serum level of free vascular endothelial growth factor and its 
95% confidence interval at baseline, 1 month and 2 months of follow‑up
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and Wu et al.6 found no significant effect of intravitreal 
bevacizumab on the IGF‑1 levels up to 2 and 8 weeks after 
therapy, respectively. In contrast, Kong et al.4 reported 
significant acute reduction at day 2 and then an increase up to 
day 42 after treatment. In the current study, in which all infants 
had PMA more than 30 weeks, IGF‑1 did not show significant 
changes up to 2 months (P = 0.062) while concentration of 
IGF‑1 in preterm infants rises after 30–32 weeks of PMA.2 The 
insignificant decrease at month 1 might be a sign of adverse 
influence of anti‑VEGF. However, we might have missed the 
acute reduction of IGF‑1 levels within the 1st week due to either 
a limited number of follow‑up visits or low power of the study 
with a small sample size.
Anthropometric measurements are routinely performed in 
the pediatric settings, being used around the world as health 
and development indices during infancy and childhood. 
In particular, weight, length, and head circumference are 
attributed to neurodevelopmental outcomes.16 Suboptimal 
postnatal growths of head circumference11 and weight12 are 
associated with the development of Type 1 ROP. Baseline 
negative z‑scores of the three main growth parameters in 
our study may be related to the study population who were 
premature infants with Type 1 ROP [Table 1].
Our results showed no systemic adverse effect up to 2 months 
after intravitreal bevacizumab, which compares favorably 
to previous studies regarding the effects of IVB in infants 
with ROP. 4‑7 However, we observed a steady decrease in the 
z‑scores of head circumference and body length [Table 1]. 
Although the current study revealed the transient systemic 
effect of IVB as well as insignificant reduction of IGF‑1 after 
bevacizumab injection, the effect of IVB on the changes in 
growth parameters cannot be overlooked by considering 
the important role of these two growth factors in organ 
development, especially neurogenesis.8,9 Moreover, weight 
z‑scores showed a different behavior; they were positive 
and were not changed significantly at 1 and 2 months after 
treatment (P = 0.358 and P = 0.225, respectively), which was 
consistent with Kong’s study6. However, the small sample size 
of our study can affect the insignificance of the results, which 
should be interpreted with caution. Therefore, we recommend 
that growth parameters, especially head circumference, should 
be meticulously examined in infants with ROP who underwent 
intravitreal bevacizumab injections. Additional studies are 
required to establish this connection.
There are several limitations in our study, including the 
small numbers of patients and few blood samplings. Future 
studies should recruit a large number of patients and have 
multiple subgroups undergo IVB injection with various 
doses and potencies to reach valid and powerful results 
about the possible “cause and effect” relationship between 
serum bevacizumab level and infantile growth parameters. 
Furthermore, we did not have a matched control group to 
compare. Since choosing a matched control group necessitates 
withholding therapy for some infants with ROP Type 1, it 
would raise ethical issues. Selecting controls from patients 
with less severe ROP would have also violated matching. 
In practice, we treat Stage 3+ ROP in zone I or zone II 
posterior with Avastin, and ROP Stage 2 and 3 with plus in 
zone II with laser. The inclusion of laser‑treated patients in 
this study as a control group could create a big confounding 
effect, where the smallest and sickest infants were treated with 
anti‑VEGF. In other words, there may be bias between the 
groups in that typically infants treated with bevacizumab are 
younger, smaller, and more fragile, and therefore may have 
different growth trajectories than those who received laser 
treatment. This can significantly affect their posttreatment 
growth rate parameters, too. Therefore, it would not be 
possible to conclude that any of the differences found in the 
various growth parameters were due to the treatment and/or 
VEGF/IGF profile. Moreover, this study has a short follow‑up 
period, which is not enough for infant neurodevelopmental 
assessment. Long‑term studies are required to determine 
whether IVB could cause neurodevelopmental impairment 
in infants with ROP and whether growth parameters such 
Figure 2: Serum level of insulin‑like growth factor‑1 and its 95% 
confidence interval at baseline, 1 month and 2 months of follow‑up
Figure 3: Changes of mean Fenton z‑scores of weight, length, and head 
circumference at baseline, 1 month and 2 months of follow‑up
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as head circumference are reliable predictive factors for 
neurodevelopment.
In conclusion, the serum levels of free VEGF were suppressed 
transiently after IVB injection, which lasted up to 2 months 
while the serum levels of IGF‑1 were not. Z‑scores of growth 
parameters in premature infants who underwent anti‑VEGF 
therapy should be measured and followed with more caution 
than individuals without anti‑VEGF therapy.
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